Stanley Laman Group Ltd. Sells 1,369 Shares of Cencora, Inc. (NYSE:COR)

Stanley Laman Group Ltd. cut its stake in Cencora, Inc. (NYSE:COR - Free Report) by 6.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,345 shares of the company's stock after selling 1,369 shares during the period. Stanley Laman Group Ltd.'s holdings in Cencora were worth $5,102,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in COR. Net Worth Advisory Group raised its stake in shares of Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after purchasing an additional 36 shares in the last quarter. Whittier Trust Co. lifted its stake in shares of Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the period. WASHINGTON TRUST Co boosted its holdings in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. JFS Wealth Advisors LLC increased its stake in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. increased its stake in shares of Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after acquiring an additional 47 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This represents a 21.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares in the company, valued at approximately $85,680,732.63. The trade was a 4.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,253 shares of company stock worth $10,582,297. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Up 0.0%

COR traded up $0.08 on Friday, reaching $295.12. 966,888 shares of the company traded hands, compared to its average volume of 1,526,444. The company has a market cap of $57.20 billion, a price-to-earnings ratio of 41.98, a PEG ratio of 1.31 and a beta of 0.58. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock's 50 day moving average price is $287.24 and its 200-day moving average price is $261.65. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $3.80 EPS. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's payout ratio is 25.52%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Bank of America boosted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Finally, Citigroup raised their price objective on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.